Ramon Dan, Shahar Jonathan, Massarweh Amir, Man Irit, Perlman Ido, Loewenstein Anat
Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Department of Ophthalmology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Transl Vis Sci Technol. 2018 Dec 7;7(6):23. doi: 10.1167/tvst.7.6.23. eCollection 2018 Nov.
To evaluate retinal toxicity of ziv-aflibercept, a drug that had been approved for use for patients with colon cancer.
Twenty-two albino rabbits were injected intravitreally with 0.1 mL of ziv-aflibercept solution into the experimental eye and 0.1-mL saline into the control eye. Twelve were used for electroretinogram (ERG) at 4-weeks follow-up. An additional 10 rabbits were used for testing penetration of ziv-aflibercept into the retina during follow-up. The visual-evoked potential (VEP) was recorded after 4 weeks of ERG follow-up. Glial fibrillary acidic protein (GFAP) immunocytochemistry and retinal histology were performed after the termination of the follow-up period.
The ERG responses of the experimental eyes did not show signs of permanent functional damage. The VEP responses of the experimental eyes were of normal pattern and amplitude, and were similar to those recorded by stimulation of the control eyes. Histologic studies of both experimental and control eyes did not show signs of structural damage. However, GFAP expression was increased in retinal Müller cells of the experimental eyes and not of the control eyes. Retinal penetration of ziv-aflibercept, as indicated by positive antihuman immunoreactivity, was observed 1 day postinjection and was strengthened during the next 7 days. At 14 days postinjection, ziv-aflibercept was not detected.
Ziv-aflibercept was found to be nontoxic to the retina of rabbits based on electrophysiologic testing and histologic examination. However, GFAP immunocytochemistry suggests mild retinal stress caused by the drug.
If proven safe, ziv-aflibercept may be a new affordable treatment option in conditions involving neovascularization and macular edema.
评估已获批用于结肠癌患者的药物阿柏西普的视网膜毒性。
22只白化兔的实验眼玻璃体内注射0.1 mL阿柏西普溶液,对照眼注射0.1 mL生理盐水。12只用于4周随访时的视网膜电图(ERG)检查。另外10只兔用于随访期间阿柏西普视网膜穿透性检测。ERG随访4周后记录视觉诱发电位(VEP)。随访期结束后进行胶质纤维酸性蛋白(GFAP)免疫细胞化学和视网膜组织学检查。
实验眼的ERG反应未显示永久性功能损害迹象。实验眼的VEP反应模式和振幅正常,与对照眼刺激记录的结果相似。实验眼和对照眼的组织学研究均未显示结构损害迹象。然而,实验眼视网膜Müller细胞中GFAP表达增加,对照眼中未增加。注射后1天观察到阿柏西普的视网膜穿透,以抗人免疫反应阳性表示,在接下来7天内增强。注射后14天未检测到阿柏西普。
基于电生理测试和组织学检查,发现阿柏西普对兔视网膜无毒。然而,GFAP免疫细胞化学提示该药物引起轻度视网膜应激。
如果被证明安全,阿柏西普可能是涉及新生血管形成和黄斑水肿病症的一种新的可负担得起的治疗选择。